Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis
Reason given: Business Decision
Key facts
- Where
- College Station, Coral Gables, Miami Lakes, Sherman Oaks, Thousand Oaks, and Webster, United StatesSee the 6 sites
- Phase
- Phase 1
Where in United States
- J&S Studies, Inc.College Station, United StatesNo longer taking part
- Driven ResearchCoral Gables, United StatesNo longer taking part
- San Marcus Research ClinicMiami Lakes, United StatesNo longer taking part
- Unison Clinical TrialsSherman Oaks, United StatesNo longer taking part
- Clinical Trials Research InstituteThousand Oaks, United StatesNo longer taking part
- Center for Clinical Studies, LTD. LLPWebster, United StatesNo longer taking part
Trial details
- Who runs it
- Xencor, Inc.
- Trial code
- NCT06005792
- Record updated
- 2 December 2025
- Original description
The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis and atopic dermatitis.Read full original descriptionShow less
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of XmAb27564 in Patients With Plaque Psoriasis and Atopic Dermatitis
The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis and atopic dermatitis.
Inclusion: The main inclusion and exclusion criteria include, but are not limited to, the following:; Have active mild-to-severe plaque psoriasis or moderate-to-severe atopic dermatitis according to study-specific criteria; Weight between 40 to 150 kg, inclusive; No topical treatments for psoriasis or atopic dermatitis for 2 weeks before randomization; No phototherapy for psoriasis for 4 weeks before randomization; Washout of oral treatments for psoriasis or atopic dermatitis for 4 weeks before randomization; Washout of biologic treatments for psoriasis or atopic dermatitis for 12 weeks before randomization; Stated willingness to comply with all study procedures (including skin biopsies) and availability for the duration of the study.
Exclusion: Patients who have had any prior investigational treatment with IL-2 therapies; Patients with a history of active asthma within 5 years of screening, except those that have well controlled asthma symptoms at screening visit.